GA
SLXP

Geneva Advisors’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Geneva Advisors’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,885
Closed -$217K – 749
2014
Q4 		$217K Sell
1,885
-315,169
-99% -$38.2M ﹤0.01% 585
2014
Q3 		$49.5M Buy
317,054
+46,314
+17% +$6.71M 0.93% 44
2014
Q2 		$33.4M Sell
270,740
-53,739
-17% -$5.94M 0.61% 65
2014
Q1 		$33.6M Buy
324,479
+305,017
+1,567% +$31.2M 0.62% 61
2013
Q4 		$1.75M Buy
+19,462
New +$1.55M 0.03% 173

Other funds holding SLXP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geneva Advisors's SLXP Position: Q1 2015 in Review

Geneva Advisors sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 1,885 shares — an estimated $217K sold.

Geneva Advisors first reported a position in SLXP in Q4 2013 and held it in 5 quarters. The position peaked at $49.5M in Q3 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • Geneva Advisors reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
  • Geneva Advisors sold 1,885 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $217K.
  • Geneva Advisors first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2013 and held it in 5 quarters.
  • Geneva Advisors's SALIX PHARMACEUTICALS LTD DEL position peaked at $49.5M in Q3 2014.
  • 298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Geneva Advisors's 13F filing for Q1 2015, filed 5 May 2015.